| Title |
Mitral valve repair with a device for artificial chordal implantation at 2 years / |
| Authors |
Weber, Alberto ; Taramasso, Maurizio ; Podkopajev, Andrej ; Janušauskas, Vilius ; Zakarkaitė, Diana ; Vogel, Rolf ; Carrel, Thierry |
| DOI |
10.1016/j.xjon.2021.08.041 |
| Full Text |
|
| Is Part of |
JTCVS open.. New York : Elsevier Inc.. 2021, vol. 8, p. 280-289.. eISSN 2666-2736 |
| Keywords [eng] |
chordal repair ; mitral regurgitation ; mitral valve repair |
| Abstract [eng] |
Objectives: This study examines the early and midterm safety, efficacy, and durability of mitral valve repair for primary mitral regurgitation (MR) using the ChordArt device (CoreMedic) for chordal replacement. Methods: Five patients with symptomatic severe primary degenerative MR due to isolated central posterior leaflet prolapse/flail were treated with the ChordArt device in a transseptal surgical approach and followed prospectively with periodical clinical and echocardiographic assessments for 2 years. Results: Reduction of MR immediately after the implantation of artificial chords was achieved in all patients showing no or trace MR (<1+/4+). In all patients, MR <1+ was maintained during 24 months of follow-up. No dehiscence, detachment, or dislocation of the implanted ChordArt devices was observed. Transthoracic echocardiography showed that left ventricle end diastolic diameter significantly decreased during the whole follow-up period in comparison to baseline condition, especially at discharge and 1-month follow-up. Left ventricle end systolic diameter also significantly decreased during the whole follow-up period in comparison to baseline condition. Left atrial volume significantly decreased during the follow-up period in comparison to discharge. No major adverse events, as defined per protocol, were observed during the intervention or during the follow-up period. Conclusions: The ChordArt device allows successful treatment of primary degenerative MR due to posterior mitral leaflet prolapse or flail, with a good safety profile and promising immediate clinical and echocardiographic benefits that are confirmed up to 24 months. |
| Published |
New York : Elsevier Inc |
| Type |
Journal article |
| Language |
English |
| Publication date |
2021 |
| CC license |
|
